Pre-clinical data show that both intravenous and intratumoral injections of CRD-5500 induce tumor regression in murine CT26 colon carcinoma models engineered to express human STING, and this anti-tumor effect is further amplified when CRD-5500 is combined with check point inhibitor therapy [92]. This evidence concerns the gene STING1 and colon carcinoma.